Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Treasury Shares (2016 - 2026)

Cytosorbents filings provide 10 years of Treasury Shares readings, the most recent being $775301.0 for Q4 2025.

  • On a quarterly basis, Treasury Shares fell 72.4% to $775301.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $775301.0, a 72.4% decrease, with the full-year FY2025 number at $775301.0, down 72.4% from a year prior.
  • Treasury Shares hit $775301.0 in Q4 2025 for Cytosorbents, down from $2.8 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $2.8 million in Q3 2025 to a low of $125340.0 in Q2 2022.
  • Median Treasury Shares over the past 5 years was $387376.0 (2021), compared with a mean of $770755.6.
  • Biggest five-year swings in Treasury Shares: skyrocketed 804.7% in 2023 and later tumbled 72.4% in 2025.
  • Cytosorbents' Treasury Shares stood at $304962.0 in 2021, then grew by 2.34% to $312092.0 in 2022, then skyrocketed by 804.7% to $2.8 million in 2023, then decreased by 0.5% to $2.8 million in 2024, then tumbled by 72.4% to $775301.0 in 2025.
  • The last three reported values for Treasury Shares were $775301.0 (Q4 2025), $2.8 million (Q3 2025), and $547335.0 (Q2 2025) per Business Quant data.